SCHEMBL3769269

SCHEMBL3769269

COC(=O)CCC(=O)Nc1[c]cccc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
POLB P06746 1/20 0.53
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPT P10636 2/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HTT P42858 2/20 0.49
HPGD P15428 1/20 0.49
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
PTPRC P08575 3/20 0.47
PTPN13 Q12923 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
CTSL P07711 1/20 0.44
GAA P10253 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5122024 0.82 MAPK1 (0.51) ALDH1A1CYP2C19MEN1KMT2AMAPT
SCHEMBL3984134 0.82 L3MBTL1 (0.53) POLBCYP1A2CYP2C19MEN1KMT2A
SCHEMBL2181710 0.80 TERT (0.41) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL5694380 0.79 CETP (0.51) ALDH1A1POLBRAB9ASMN1; SMN2KDM4E
SCHEMBL7795577 0.79 CA12 (0.42) ALDH1A1KMT2AMAPTSMN1; SMN2HTT
SCHEMBL27726466 0.79 KMT2A (0.38) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL1133942 0.78 MAPT (0.47) ALDH1A1POLBCYP1A2CYP2C19MEN1
SCHEMBL6201463 0.78 NPC1 (0.51) ALDH1A1POLBMEN1KMT2ARAB9A
SCHEMBL3760355 0.77 MAPK1 (0.51) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL3221873 0.77 CETP (0.54) POLBMEN1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA ALDH1A1 3061/4885POLB 2137/4885CYP1A2 3200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.